Skip to main content
ENDPinactive

Endo International plc

·Phase 3
ImmunologyPainMusculoskeletal

ENDP evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for ENDP—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

4.8/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

—

Lead Asset

xiaflex (Preclinical)

Next Catalyst

—

Financial data as of Dec 31, 2023.

Tracking 1 pipeline candidate · 3 clinical trials for Endo International plc.

Run Endo International plc through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Endo International plc facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway10.0

Profitable (positive operating cash flow)

Financial Health4.0

OCF $115M · Net income -$2.4B · Debt/OCF 15.5×

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Frequently asked questions

What is Endo International plc's lead drug candidate?

Endo International plc's most advanced tracked candidate is xiaflex (Preclinical) for plantar fasciitis.

What therapeutic areas does Endo International plc focus on?

Endo International plc develops therapies across Immunology, Pain, Musculoskeletal.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.